

Article

Trefoil Family Factor Peptide 1—A New Biomarker in Liquid Biopsies of Retinoblastoma under Therapy

Maike Anna Busch ^{1,*}, André Haase ^{1,†}, Emily Alefeld ¹, Eva Biewald ², Leyla Jabbarli ² and Nicole Dünker ¹

¹ Institute of Anatomy II, Department of Neuroanatomy, Medical Faculty, Center for Translational Neuro and Behavioral Sciences (C-TNBS), University of Duisburg-Essen, 45147 Essen, Germany; andre.haase@uk-essen.de (A.H.); emily.alefeld@stud.uni-due.de (E.A.); nicole.duenker@uk-essen.de (N.D.)

² Department of Ophthalmology, Children's Hospital, University of Duisburg-Essen, 45147 Essen, Germany; eva.biewald@uk-essen.de (E.B.); leyla.jabbarli@uk-essen.de (L.J.)

* Correspondence: maike.busch@uk-essen.de; Tel.: +49-201-723-84434

† These authors contributed equally to this work.

Simple Summary: Effective management of retinoblastoma (RB), a common childhood eye cancer, requires accurate diagnosis and monitoring during therapy. In this study, the liquid biopsy marker potential of the secreted trefoil family factor peptide 1 (TFF1), described as a biomarker of a more advanced RB subtype, was explored. TFF1 expression levels were investigated in aqueous humor (AH) of RB patients after enucleation and in RB patients undergoing intravitreal chemotherapy, and compared with TFF1 expression levels in RB patients' blood serum. AH showed consistent TFF1 levels in a subgroup of RB patients, remarkably decreasing post-therapy in responsive patients. The blood serum of RB patients only displayed low-to-non-detectable and therapy-independent TFF1 levels. The study suggests TFF1 expression in AH is a reliable biomarker, aiding RB diagnosis and treatment assessment and highlights its potential for non-invasive RB therapy monitoring.

Abstract: Effective management of retinoblastoma (RB), the most prevalent childhood eye cancer, depends on reliable monitoring and diagnosis. A promising candidate in this context is the secreted trefoil family factor peptide 1 (TFF1), recently discovered as a promising new biomarker in patients with a more advanced subtype of retinoblastoma. The present study investigated TFF1 expression within aqueous humor (AH) of enucleated eyes and compared TFF1 levels in AH and corresponding blood serum samples from RB patients undergoing intravitreal chemotherapy (IVC). TFF1 was consistently detectable in AH, confirming its potential as a biomarker. Crucially, our data confirmed that TFF1-secreting cells within the tumor mass originate from RB tumor cells, not from surrounding stromal cells. IVC-therapy-responsive patients exhibited remarkably reduced TFF1 levels post-therapy. By contrast, RB patients' blood serum displayed low-to-undetectable levels of TFF1 even after sample concentration and no therapy-dependent changes were observed. Our findings suggest that compared with blood serum, AH represents the more reliable source of TFF1 if used for liquid biopsy RB marker analysis in RB patients. Thus, analysis of TFF1 in AH of RB patients potentially provides a minimally invasive tool for monitoring RB therapy efficacy, suggesting its importance for effective treatment regimens.

Keywords: retinoblastoma; TFF1; aqueous humor; liquid biopsy; therapy monitoring



Citation: Busch, M.A.; Haase, A.; Alefeld, E.; Biewald, E.; Jabbarli, L.; Dünker, N. Trefoil Family Factor Peptide 1—A New Biomarker in Liquid Biopsies of Retinoblastoma under Therapy. *Cancers* **2023**, *15*, 4828. <https://doi.org/10.3390/cancers15194828>

Academic Editor: Eric C. Beyer

Received: 21 August 2023

Revised: 1 September 2023

Accepted: 14 September 2023

Published: 2 October 2023



Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Retinoblastoma (RB), the most common pediatric ocular malignancy, arises from the uncontrolled proliferation of developing retinal cells [1,2]. RB is characterized by the loss or mutation of both copies of the *RB1* gene, which regulates the cell cycle and inhibits tumorigenesis [3–6]. The disease manifests predominantly in children under five years of age,

affecting both eyes in approximately 40% of all cases [5]. If left untreated, retinoblastoma can lead to severe visual impairment and, in the most unfavorable cases, metastatic spread into the central nervous system via the optic nerve [1,7,8]. Prevalent RB therapies comprise invasive procedures such as enucleation of the affected eye, leading to lifetime visual limitations, or systemic chemotherapy, bearing various risks for the young patients [9–11]. Intravitreal chemotherapy (IVC) has emerged as a highly effective therapeutic RB modality, particularly for intraocular tumors [12–18]. IVC chemotherapeutic agents are directly injected into the vitreous cavity of the affected eye, allowing for targeted treatment and reduced systemic toxicity. While IVC has shown promising results in managing RB, therapy monitoring remains crucial for the assessment of treatment efficacy and early detection of potential recurrence. A tissue biopsy is generally considered contraindicated for RB, as it is believed to promote extraocular spread [19]. Nevertheless, in some cases, tissue biopsy is relevant as it allows for a reliable confirmation of RB diagnosis and the assessment of the *RB1* mutational status for prognostic counseling [20]. Despite the use of optical coherence tomography and B-scan ultrasonography, various ocular diseases such as Coats disease, persistent fetal vasculature, retinopathy of prematurity, coloboma, and toxocariasis may be misdiagnosed as RB [19], eventually resulting in enucleation of infants for questionable diagnostic purposes [21].

Liquid biopsy offers a non-invasive alternative, helping to overcome the limitations of tumor biopsies. The term liquid biopsy (LB) refers to the detection of tumor-derived components, such as circulating tumor cells (CTCs), cell-free DNA (cfDNA), exosomes, microRNAs, and other secreted factors, in easily accessible body fluids like blood or aqueous humor (AH) [22–24]. LB allows for early detection of cancer, stratification of therapeutic intervention as well as monitoring of therapy effectiveness, and detection of metastatic relapses caused by therapy resistance [25]. Aqueous humor paracentesis is a straightforward and safe LB procedure commonly conducted under general anesthesia in conjunction with eye examinations in RB infants. AH aspiration can also be combined with intravitreal administration of chemotherapy [24]. In recent decades, the identification of specific biomarkers—also detectable in LBs—revolutionized cancer research and clinical practice [26–28]. Biomarkers are measurable indicators of biological processes or disease states and play a crucial role in early detection, diagnosis, and prognosis of various malignancies including RB [29,30]. They also provide an opportunity to develop targeted therapies and allow for real-time monitoring of cancer progression and treatment response [31,32].

Potential RB biomarkers comprise histone modification and DNA methylation markers, components of non-coding RNA regulation mechanisms, as well as proteomic and radiogenomic markers (for review see: [33]). Only a few of these potential biomarkers are, however, assessable by non-invasive procedures like LBs, e.g., in the AH and/or blood serum of RB patients. Examples are lactate dehydrogenase [34,35], survivin [36], transforming growth factor beta (TGF- β) [37], and trefoil factor family peptide 1 (TFF1). The latter has emerged as an intriguing candidate with promising implications for cancer management [1,22,38]. TFF1, a member of the trefoil factor family peptides, plays a crucial role in maintaining mucosal integrity and promoting epithelial repair in various tissues [39–42]. Previous studies by our group showed that RB cell lines and RB tumors express variable levels of TFF1 [43–45], while it is not expressed in the healthy human retina. Recent studies suggested a potential link between TFF1 and specific clinico-pathological tumor features, suggesting its diagnostic and prognostic value as an RB biomarker [1,23]. Most recently, we demonstrated that TFF1 is also detectable in the AH of RB patients [23], rendering it a highly promising candidate as an RB biomarker in LBs. As a secreted, extracellular protein, TFF1 can be detected in body fluids [23,46,47], circumventing the need for invasive procedures. Additionally, a prospective biomarker like TFF1 potentially aids with early cancer detection, monitoring treatment response, and assessing disease progression, thereby improving patient outcomes.

The objective of this study was to shed light onto the potential of TFF1 as a non-invasive diagnostic and prognostic RB marker in LBs. Monitoring TFF1 levels in RB patients' AH and blood may not only enable early cancer detection, but also serve as a valuable indicator for therapy efficacy. Changes in TFF1 expression or release during the course of RB treatment might provide insights into treatment response, and their monitoring prospectively helps identify patients that may require additional interventions. Integrating TFF1 assessment into LB protocols for RB patients could enhance therapeutic decision making and improve long-term outcomes. As such, a comprehensive understanding of TFF1 as a cancer biomarker potentially changes future RB diagnostics and personalized treatment approaches, ultimately contributing to improved clinical outcomes and quality of life for affected children.

2. Materials and Methods

2.1. Human Retinoblastoma Tumor, Aqueous Humor, and Blood Samples

Human retinoblastoma (RB) primary tumor material, aqueous humor samples from enucleations of 8 patients, as well as aqueous humor and blood serum samples from 7 RB patients under therapy and 6 healthy individuals (control group) were used for TFF1 expression studies. The Ethics Committee of the Medical Faculty of the University of Duisburg-Essen approved the use of retinoblastoma samples (approval # 14-5836-BO) for research conducted in the course of this study, and written informed consent has been obtained from patients' relatives or parents.

Primary tumor material and aqueous humor samples of eight patients were harvested immediately after enucleation (T27, T31, T32, T34, T36, T38, T40, and T41). For AH paracentesis from the anterior eye chamber, a 30 G needle was used. Subsequently, the optic bulb was fenestrated and the tumor was extracted. Aqueous humor and blood serum samples of seven patients were harvested under anesthesia prior to IVC treatment with melphalan. Subsequently, blood was centrifuged at $2500 \times g$ for 15 min at 18°C . Separated serum fraction aliquots were stored at minus 80°C until further use. Additionally, blood was drawn from six healthy individuals as a control group. Aqueous humor was stored at minus 80°C until use or further processing (see below), and tumor tissue samples were cultured as described below.

This study includes a case series of eight untreated eyes from individual children diagnosed with intraocular retinoblastoma (in 2022) and seven treated eyes from individual children diagnosed with intraocular retinoblastoma between 2022 and 2023. Diagnosis of the untreated eyes was confirmed by a specialized pathologist after enucleation. The data collected included patient's age at diagnosis, gender, laterality, ICRB stage (International Classification of Retinoblastoma), RB1 mutation status, tumor volume/size, optic nerve, and choroid invasion.

2.2. Primary RB Cell Culture

After the primary RB tumor material was dissected into small fragments using a sterile blade, it was washed in PBS and centrifuged three times at 800 rpm for 2 min. Afterwards, the tumor material was cultivated in supplemented Dulbecco's modified Eagle's medium (DMEM; PAN-Biotech, Aidenbach, Germany) under conditions described previously [48]. The cells separated in culture into suspension (RB tumor cells) and adherent populations (RB-derived stroma cells) and were subsequently cultured separately. Supernatants from both subcultures were harvested and residual cells were removed by centrifugation. Cell culture supernatants were kept at -20°C until usage.

2.3. Blood Serum Concentration and TFF1 ELISA Analysis

Right before use, blood serum samples were concentrated up to 5-fold using protein concentrator column (3 kDa MWCO, Thermo Fischer Scientific, MA, USA) following the manufacturer's instructions. One hundred microliters of aqueous humor samples and concentrated blood serum from RB patients was analyzed using a human TFF1 ELISA kit

(ab213833, abcam, Cambridge, UK) according to the manufacturer's protocol. The standard curve included in the kit was used to determine the concentration of the samples analyzed. A workflow diagram is shown in Figure 1.




Figure 1. Workflow diagram of the TFF1 ELISA analysis. IVC: intravitreal chemotherapy. Created with [BioRender.com](https://www.biorender.com) (accessed on 13 September 2023).

2.4. Immunohistochemistry and Immunofluorescence Stainings

RB tumors were immunohistochemically stained using a specific TFF1 antibody (1:200, abcam, Cambridge, UK, # ab92377). Staining was revealed using a Vectastin Elite ABC kit (Vector Laboratories, Burlingame, CA, USA) following a protocol previously described by our group [48]. For visual documentation, an Aperio ScanScope AT2 (Leica, Wetzlar, Germany) slide scanner was used.

For immunofluorescence staining of TFF1, 1×10^5 cells were seeded on coverslips coated with poly-D-lysine (Sigma, Hamburg, Germany) and stained as previously described by our group [23]. Pictures were taken with a NIKON Eclipse E600 microscope equipped with a digital camera and NIKON Eclipse net software (version 5.20.02).

2.5. Statistical Analysis

Statistical analyses were performed using GraphPad Prism 9. Results were analyzed by a Student's t-test and considered significantly different if * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, or **** $p < 0.0001$.

3. Results

3.1. Soluble TFF1 in Aqueous Humor of RB Patients Is Secreted by RB Tumor Cells

In a very recent study, we discovered TFF1 expression in a specific subgroup of retinoblastoma (RB) tumors with advanced stages, and found this soluble peptide to be secreted into the aqueous humor of RB patients [23]. To expand our investigation to a larger cohort of RB patients, we analyzed aqueous humor (AH) samples from eight additional RB patients after enucleation. Table 1 summarizes the clinical and pathological characteristics of the RB patients analyzed.

Using a specific, highly sensitive TFF1 ELISA (Figure 2a) allowed us to confirm that RB tumor cells secrete soluble TFF1 into the aqueous humor of RB patients' eyes.

Six out of eight tumors analyzed secreted high concentrations of TFF1 (ranging between 1000 and 4500 pg/mL; labeled as T27, T36, T31, T40, and T41) into the AH. Additionally, we found one tumor (T38) with moderate levels of TFF1 secretion. Only one (T32) out of eight tumors did not secrete any detectable TFF1 into the AH.

Table 1. Comparison of RB patients' clinical parameters and pathology reports with TFF1 levels in aqueous humor (AH). na: not available, *n*: number in each group, *N*: total number, ICRB: International Classification of Retinoblastoma.

	TFF1 Expressed <i>n</i> (%)	TFF1 Not Expressed <i>n</i> (%)	<i>N</i>
Patient's	7 (87.5)	1 (12.5)	8
Sex			
female	2 (28.6)	0 (0)	2
m	5 (71.4)	1 (100)	6
ICRB stage			
D	1 (14.3)	0 (0)	1
E	4 (57.1)	1 (100)	5
na	2 (28.6)	0 (0)	2
Laterality			
unilateral	7 (100)	1 (100)	8
bilateral	0 (0)	0 (0)	0
Age at diagnosis			
<18 month	0 (0)	1 (100)	1
18–36 month	6 (85.7)	0 (0)	6
>36 month	1 (14.3)	0 (0)	1
Tumor volume			
<1 cm ³	1 (14.3)	0 (0)	1
2–3 cm ³	2 (28.6)	0 (0)	2
>3 cm ³	4 (57.1)	1 (100)	5
Optic nerve invasion			
none	5 (71.4)	1 (100)	6
p-laminar	2 (28.6)	0 (0)	2
post-laminar	0 (0)	0 (0)	0
Choroid invasion			
none	7 (100)	1 (100)	8
invasion	0 (0)	0 (0)	0

In order to compare the expression pattern of TFF1 in AH with its expression in original RB tumor specimens, we performed immunohistochemical staining for TFF1 on paraffin sections of enucleated patients' eyes, barring the investigated tumors. Remarkably, all tumors displaying detectable TFF1 in the AH samples also stained positive for TFF1 in the primary tumor sections (Figure 2b).

These results further support our previous findings and indicate that detection of TFF1 in RB patients' AH represents a reliable marker for the presence of TFF1-secreting RB tumor cells. This finding holds promise for potential applications in RB patient monitoring and treatment strategies.

To investigate whether TFF1 is exclusively secreted by RB tumor cells and not by surrounding stromal tissue, we compared supernatants of a primary stromal cell culture and a primary RB tumor cell culture, both derived from enucleations of RB-tumor-bearing patient eyes. The primary stromal cells did not carry the RB1 mutation present in the primary RB tumor cells, indicating their non-tumor identity. As expected, ELISA analysis revealed no detectable TFF1 secretion in the supernatant of the stromal cell culture.

To further validate these results, we conducted immunofluorescence staining to assess the cellular expression of TFF1. The intracellular TFF1 expression pattern closely correlated with the TFF1 secretion status observed in the RB tumor cells and RB-tumor-derived stromal cells. Specifically, primary RB tumor cells exhibited high levels of TFF1 expression (Figure 3a), while the corresponding RB-derived stromal cells showed no detectable TFF1 expression (Figure 3b).




Figure 2. TFF1 expression analyses in aqueous humor samples and corresponding histological analysis of RB tumors in enucleated eyes of RB patients. **(a)** TFF1 ELISA analysis of 8 aqueous humor samples of RB patients, displaying six tumors highly expressing TFF1 (>400 pg/mL), one patient's tumor with average TFF1 expression (30–400 pg/mL), and one patient without TFF1 expression (0–30 pg/mL) in the aqueous humor. Vertical dotted lines indicate three TFF1 expression levels. **(b)** TFF1 expression in the corresponding primary tumors is shown exemplarily for T34 (high TFF1 expression in AH), T38 (moderate TFF1 expression in AH), and T32 (no TFF1 expression in AH). Immunohistochemistry was revealed using diaminobenzidine detection (brown signal) and hematoxylin counterstaining (blue nuclei staining). Scale bars: 300 μ m.




Figure 3. Immunofluorescence TFF1 staining of primary RB cell cultures. **(a)** Pictures of a primary cell culture of RB tumor cells and **(b)** corresponding RB-tumor-derived stromal cells in DAPI (blue), TFF1 (red), and merged DAPI/TFF1 immunofluorescence staining (200 $\times$). RB tumor cells showed a high expression of TFF1, in contrast to the corresponding stromal cells displaying no TFF1 expression. Scale bars: 50 μ m.

In summary, our previous findings [23] were confirmed by analyzing AH samples from enucleated RB eyes via TFF1 ELISA. Additionally, we demonstrated that the cells secreting TFF1 originate from tumorigenic cells and not from the stromal compartment of the RB tumor mass. This discovery highlights TFF1 as a potential marker for minimally invasive therapy monitoring via AH aspiration.

3.2. Analysis of Soluble TFF1 Secretion in AH and Blood of RB Patients under Therapy

Monitoring and diagnosing RB is crucial in order to distinguish it from other diseases, evaluate treatment effectiveness, and identify potential recurrences. However, as RB tumor biopsies are not feasible, there is an urgent need for reliable biomarkers to determine diagnosis and treatment success in non-enucleated RB tumors.

To investigate if the expression of secreted TFF1 changes in liquid biopsies during therapy, we examined a series of AH and corresponding blood samples from seven RB patients using TFF1 ELISA. Liquid biopsies (AH and blood) were collected before the indicated intravitreal chemotherapy (IVC) treatment cycles with melphalan. We found that three out of the seven RB patients (T28, T33, and T44) expressed soluble, secreted TFF1 in their AH (Figure 4a).




Figure 4. TFF1 expression analyses in aqueous humor samples of RB patients during therapy. (a) TFF1 ELISA analysis of three aqueous humor samples of RB patients taken prior to the indicated intravitreal chemotherapy (IVC) cycle with melphalan. All three patients initially expressed TFF1 (30–400 pg/mL) in the aqueous humor. Values below the vertical dotted line represent no TFF1 expression (0–30 pg/mL). (b) Fundoscopy pictures of the three RB patients prior (initial) and after IVC with melphalan. For patient T28, a picture of the relapse after 5 months is provided.

The first AH sample of the tumor with the highest AH TFF1 concentration (T44) observed in our study was received from the clinics after two IVC cycles with melphalan. Thus, no information about the initial TFF1 concentration in the AH prior to therapy is available. We nevertheless included this specimen in our monitoring due to a remarkable decrease in TFF1 levels under therapy, which dropped to zero after only one additional IVC cycle.

Similarly, the tumor with the second-highest AH TFF1 concentration (T33) displayed a reduction to zero after only two therapy cycles. Interestingly, the treatment outcome seems to correlate with the reduction in TFF1 expression in the AH in all RB tumors. Both tumors with TFF1 expression dropping to zero during IVC therapy responded well to treatment and showed positive outcomes as revealed by funduscopy (Figure 4b) displaying a regression and calcification of the vitreous seeding. On the other hand, patient T28, while exhibiting a constant TFF1 expression in the AH during therapy (Figure 4a, IVC cycle 1–3), exhibited a relapse after five month (Figure 4b), while still expressing high TFF1 levels in the AH (Figure 4a, IVC cycle 4).

These findings suggest that monitoring soluble TFF1 levels in the aqueous humor of RB patients under therapy could serve as a potential biomarker to assess treatment efficacy and predict therapeutic outcomes in non-enucleated RB tumors. This could significantly improve RB therapy management and patient care.

Additionally, we examined corresponding blood serum samples from the seven RB patients who underwent therapy and compared them with three control samples from non-RB children and three healthy adolescents. Detecting TFF1 in blood serum required prior concentration of the samples (as described in the materials and methods section) and even after concentration, only fairly low TFF1 levels (~10 pg/mL) were detectable. Comparing TFF1 levels among individuals of the control groups, we found young non-RB-bearing children under the age of six to display no detectable TFF1 expression compared with the healthy adolescent group (>14 years), expressing low levels of about 10 pg/mL TFF1 (Figure 5).




Figure 5. TFF1 expression analyses in blood serum and aqueous humor samples. (a) Comparison of TFF1 blood serum levels in control groups of non-RB children under the age of 6 years with healthy individuals over 14 years. (b) Comparison of TFF1 blood serum levels (serum) with TFF1 expression in aqueous humor (AH) of patient T24. Values are means of three samples $\pm$ SEM. **** $p < 0.0001$ statistical differences compared with the control group calculated by Student's *t*-test.

Among the seven RB serum samples investigated, we detected low concentrations of TFF1 in three samples (<12 pg/mL). However, in these patients, no TFF1 was detectable in the AH. Notably, one of the RB patients displaying detectable TFF1 expression in the blood was already 13 years old (Figure 5b), suggesting that serum expression might be related to the patient's age.

In one RB patient, TFF1 expression was neither detectable in the blood nor in the AH (T26, Table 2). Furthermore, patient T28, whose TFF1 expression in AH remained unchanged during therapy, showed no detectable TFF1 expression in their blood serum (Table 2). For patients T33 and T44, whose AH TFF1 expression dropped to zero under therapy, TFF1 expression was only randomly found in individual blood serum samples without a distinct expression pattern (Table 2).

Overall, no therapy-dependent changes in TFF1 expression were detectable in the blood serum of any of the RB patients studied (Table 2), rendering blood serum unsuitable for TFF1 biomarker analyses. These findings indicate that AH remains the most reliable source for monitoring TFF1 levels and assessing treatment responses in RB patients.

Table 2 summarizes clinical and pathological characteristics as well as TFF1 expression levels found in AH and blood serum samples of the seven RB patients analyzed during therapy.

Table 2. Clinical and pathological characteristics of RB patients under IVC therapy with melphalan stratified by TFF1 expression in liquid biopsies (aqueous humor and blood serum). Red and blue labeling indicates the respective tumor analyzed in case of bilaterality.

Case	Sex	Age at Diagnosis (Month)	Laterality	ICRB Stage	Tumor Size (mm)	Enucleation	Optic Nerve Invasion (MRI)	Choroid Invasion (MRI)	RB1 Mutation	Sample Number	AH TFF1 (pg/mL)	Serum TFF1 (pg/mL)
T24 #	m	t: 23 r: 148	b	ri: B le: E	ri: 4.5 le: >10	le: PE	no	no	yes	1	0	9.73
										2	0	9.97
										3	0	11.12
T25	f	18	u	D	8.7	no	no	yes	no	1	0	11.55
										2	0	0
										3	0	10.6
										4	0	0
										5	0	0
										6	0	0
T26	m	14	b	D	9 (both)	ri: no le: SE	no	ri: no le: yes	yes	1	0	0
										2	0	0
										3	0	0
T28 #	f	t: 23 r: 51 r2: 56	b	E	ri: 12 le: 20	ri: no le: PE	ri: no le: yes	ri: no le: yes	yes	1	118.98	0
										2	124.37	0
										3	95.9	0
										4	119.41	0
T33	m	24	u	D	n/a	no	n/a	n/a	n/a	1	180.21	10.65
										2	54.28	9.23
										3	0	0
										4	0	0
										5	0	0
										6	0	9.33
										7	0	0
										8	0	0
										9	0	9.83
										10	0	10.14
										11	0	0
T39	f	26	b	ri: E le: D	ri: 22 le: 7	ri: SE le: no	ri: yes le: no	ri: yes le: no	yes	1	0	9.93
										2	0	0
										3	0	9.98
T44	m	62	u	C	8	no	no	no	n/a	1 *	340.58	10.57
										2	0	9.84

m: male, f: female, u: unilateral, b: bilateral, ri: right, le: left, t: primary tumor, r: relapse, r2: second relapse, ICRB: International Classification of Retinoblastoma, SE: secondary enucleation, PE: primary enucleation, n/a: not available, #: relapse was analyzed by TFF1 ELISA, *: specimen after two cycles of melphalan, AH: aqueous humor, MRI: magnetic resonance imaging.

4. Discussion

In contrast to other cancer entities, molecular characterization of RB tumors mainly relies on tumor samples derived from enucleations, as direct tumor biopsies bear the risk of cancer cell seeding and spread outside the eye [49–51]. The identification of tumor biomarkers in RB liquid biopsies like aqueous humor and blood serum holds the potential to improve diagnosis and therapy management of this childhood eye cancer without the need for enucleation. Aqueous humor has been suggested as a surrogate for RB tissue [26,52]. It can safely be aspirated from RB eyes and contains tumor-derived cfDNA, proteins, and metabolic targets, but also potential biomarkers like TFF1 [13,16,23,52–58]. Paracentesis of AH is minimally invasive as it is routinely aspirated from RB eyes undergoing salvage therapy with intravitreal injection of chemotherapeutics like melphalan. Nevertheless, a fine-gauge needle penetrates the cornea and thus, the procedure bears a minimal risk of complications such as bleeding, infection, cataract formation, iris trauma, and also potential spread of tumor cells [59]. Against this background, one might speculate if blood, a less invasive LB, might serve as a source for RB biomarkers like TFF1.

Our present study aimed to explore the potential of TFF1 as an RB biomarker in AH and blood serum of patients in general, and under therapy in particular. Monitoring LB biomarker levels during RB diagnosis and under therapy may ultimately enable a timely correlation between TFF1 expression levels in AH and/or blood serum and RB progression. TFF1 has previously been identified as a functional biomarker in various other

types of tumors, such as breast cancer [60,61], esophageal squamous cell carcinoma [62], and gastric cancer [63]. Notably, in breast cancer, a correlation between elevated TFF1 expression in blood samples of patients with, compared with those without, metastatic disease was observed [64]. By evaluating TFF1 staining in tumor sections post-enucleation, we and others already suggested TFF1 as a potential biomarker for a specific subset of retinoblastomas [1,38]. We previously demonstrated that TFF1 correlates with a higher clinical tumor-node-metastasis (TNM) stage and poorly differentiated tumor cells [38], later identified and specified as RB subtype 2 with a higher risk of metastasis by Liu et al. [1]. Most recently, we revealed for the first time that soluble TFF1 is secreted into the AH of RB patients [23].

Here, we analyzed AH of eight patients after enucleation as well as AH and corresponding blood serum of seven RB patients under therapy for TFF1 expression and secretion status. In addition, we investigated TFF1 expression in blood serum samples of control specimens including young children and adolescents in order to compare TFF1 levels of both groups.

The study presented verifies our previous findings [23] that TFF1 is secreted into the AH of most patients analyzed after enucleation. All patients with TFF1-positive AH also expressed TFF1 in the original tumor. Furthermore, we investigated if TFF1 is secreted exclusively by RB tumor cells or also by tumor-associated stromal cells. We therefore analyzed primary RB tumor cells and compared their endogenous TFF1 expression status and ability to secrete TFF1 into the supernatant with RB-tumor-derived stromal cells. We were able to demonstrate that only RB tumor cells and not RB-derived stromal cells express and secrete TFF1, rendering TFF1 a specific marker for RB tumor cells.

Three out of seven RB patients' tumors secreted soluble TFF1 into the AH under therapy. Two of these patients completely lost TFF1 expression in their AH during IVC therapy with melphalan, indicating a direct influence of the therapy regimen on TFF1 expression. The most obvious mechanistic explanation for this loss is death of TFF1-expressing RB tumor cells in the course of therapy. If this holds true, TFF1 expression is a direct indicator for residual-therapy-surviving and TFF1-secreting tumor cells. In line with these results, one RB tumor investigated displayed unvaried high TFF1 secretion into the AH during therapy and developed a relapse after five months, possibly indicating persisting RB tumor cells not readily visible in funduscopy and sonography. One might hypothesize that tumors with a high stromal content respond particularly well to therapy. If, however, mainly stromal, and not tumor, cells are susceptible to treatment, this distinction cannot be made by funduscopy. In this case, TFF1 would be an extraordinarily helpful marker for monitoring residual RB tumor cells. If these therapy-resistant cells still secrete TFF1, the urgent need for more frequent post-therapy screenings of the respective RB patients was indicated. However, not all RB tumors express and/or secrete TFF1 into the AH. Thus, TFF1 can probably not be considered a general minimally invasive LB-based RB biomarker, but might emerge as highly beneficial for patients with a more aggressive subtype 2 RB tumor.

Furthermore, we investigated if TFF1 can also be detected in the blood serum of RB patients and if TFF1 levels might correlate with therapy efficacy. Some RB patients' blood samples displayed detectable, yet very low, concentrations of soluble TFF1. No correlation of TFF1 levels in blood serum and corresponding AH samples was discernible and TFF1 expression likewise did not correlate with RB treatment outcome. Even in the control groups, only very low concentrations of TFF1 were detectable. Thus, AH seems to be superior to blood serum as an LB for RB, not only for detecting tumor-associated chromosomal changes in whole genome sequencing [59], but also for TFF1 monitoring. Interestingly, however, no TFF1 expression was detectable in non-RB children under the age of 6 in comparison to the older, adolescent control group (>13 years), who displayed low, but traceable levels. This may lead to the assumption that healthy young children do not secrete TFF1 into the blood.

Summarizing, one can state that the analysis of TFF1 in the AH of RB patients opens the field for additional diagnostic approaches and therapy monitoring, using TFF1 as a potential biomarker for RB tumor cells. In the future, AH paracentesis might add to the standard diagnostic RB procedure as well as to the monitoring of therapy outcomes by sonography, funduscopy, and MRI and potentially improve early detection of residual RB tumor cells in follow-up screenings (Figure 6).




Figure 6. Potential monitoring procedures of RB patients under treatment to improve the outcome. MRI: magnetic resonance imaging; AH: aqueous humor; ctDNA: circulating tumor DNA; miRNA: micro RNA. Created with ©BioRender.com.

Nevertheless, it is necessary to further investigate TFF1 secretion into the AH during therapy in a larger cohort of RB patients to develop a save future implementation of TFF1 in clinical diagnostic and treatment regimens.

5. Conclusions

We succeeded in providing evidence for therapy-dependent changes in TFF1 expression in the AH of RB patients. Our data strongly suggest TFF1 as an LB-based RB biomarker allowing for minimally invasive, early, and unequivocal detection of RB. As TFF1 is supposed to be a marker of a subset of more advanced RB tumors with a higher risk for metastases, routinely screening for its expression might also enable a stratification of personalized intervention prior to therapy and monitoring of treatment effectiveness in the course of therapy, as well as detection of metastatic relapses caused by therapy resistance.

Author Contributions: Conceptualization, M.A.B.; methodology, A.H. and E.A.; validation, M.A.B. and A.H.; formal analysis, A.H. and E.A.; investigation, A.H. and E.A.; resources, E.B. and L.J.; data curation, A.H. and M.A.B.; writing—original draft preparation, M.A.B. and N.D.; writing—review and editing, M.A.B. and N.D.; visualization, M.A.B. and A.H.; supervision, M.A.B. and N.D.; project administration, M.A.B. and N.D. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding. We acknowledge support by the Open Access Publication Fund of the University of Duisburg-Essen.

Institutional Review Board Statement: The study was conducted in accordance with the guidelines of the Declaration of Helsinki, and approved by the Ethics Committee of the Medical Faculty of the University of Duisburg-Essen (approval # 06-30214; date of approval: 5 December 2006; approval # 14-5836-BO; date of approval: 11 March 2020).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: The data presented in this study are available on request from the corresponding author.

Acknowledgments: The authors would like to thank N. Bechrakis and T. Kiefer for their valuable support and A. Bollmeier for excellent technical assistance.

Conflicts of Interest: The authors declare no conflict of interest.

References

- Liu, J.; Ottaviani, D.; Sefta, M.; Desbrousses, C.; Chapeaublanc, E.; Aschero, R.; Sirab, N.; Lubieniecki, F.; Lamas, G.; Tonon, L.; et al. A high-risk retinoblastoma subtype with stemness features, dedifferentiated cone states and neuronal/ganglion cell gene expression. *Nat. Commun.* **2021**, *12*, 5578. [\[CrossRef\]](#) [\[PubMed\]](#)
- Singh, H.P.; Wang, S.; Stachelek, K.; Lee, S.; Reid, M.W.; Thornton, M.E.; Craft, C.M.; Grubbs, B.H.; Cobrinik, D. Developmental stage-specific proliferation and retinoblastoma genesis in RB-deficient human but not mouse cone precursors. *Proc. Natl. Acad. Sci. USA* **2018**, *115*, E9391–E9400. [\[CrossRef\]](#) [\[PubMed\]](#)
- Dimaras, H.; Corson, T.W. Retinoblastoma, the visible CNS tumor: A review. *J. Neurosci. Res.* **2018**, *97*, 29–44. [\[CrossRef\]](#)
- Bornfeld, N.; Lohmann, D.; Bechrakis, N.E.; Biewald, E. Retinoblastom. *Ophthalmologe* **2020**, *117*, 389–402. [\[CrossRef\]](#) [\[PubMed\]](#)
- Roy, S.R.; Kaliki, S. Retinoblastoma: A Major Review. *Mymensingh Med. J.* **2021**, *30*, 881–895.
- Bouchoucha, Y.; Matet, A.; Berger, A.; Carcaboso, A.M.; Gerrish, A.; Moll, A.; Jenkinson, H.; Ketteler, P.; Dorsman, J.C.; Chantada, G.; et al. Retinoblastoma: From genes to patient care. *Eur. J. Med. Genet.* **2023**, *66*, 104674. [\[CrossRef\]](#)
- Chronopoulos, A.; Babst, N.; Schiemenz, C.; Schutz, J.S.; Heindl, L.M.; Ranjbar, M.; Kakkassery, V. A Narrative Review—Therapy Options and Therapy Failure in Retinoblastoma. *Neurosignals*. **2022**, *30*, 39–58. [\[CrossRef\]](#)
- Shields, C.L.; Bas, Z.; Laiton, A.; Silva, A.M.V.; Sheikh, A.; Lally, S.E.; Shields, J.A. Retinoblastoma: Emerging concepts in genetics, global disease burden, chemotherapy outcomes, and psychological impact. *Eye* **2023**, *37*, 815–822. [\[CrossRef\]](#)
- Kaewkhaw, R.; Rojanaporn, D. Retinoblastoma: Etiology, Modeling, and Treatment. *Cancers* **2020**, *12*, 2304. [\[CrossRef\]](#)
- Munier, F.L.; Beck-Popovic, M.; Chantada, G.L.; Cobrinik, D.; Kivelä, T.T.; Lohmann, D.; Maeder, P.; Moll, A.C.; Carcaboso, A.M.; Moulin, A.; et al. Conservative management of retinoblastoma: Challenging orthodoxy without compromising the state of metastatic grace. “Alive, with good vision and no comorbidity”. *Prog. Retin. Eye Res.* **2019**, *73*, 100764. [\[CrossRef\]](#)
- Temming, P.; Arendt, M.; Viehmann, A.; Eisele, L.; Le Guin, C.H.D.; Schündeln, M.M.; Biewald, E.; Astrahantseff, K.; Wieland, R.; Bornfeld, N.; et al. Incidence of second cancers after radiotherapy and systemic chemotherapy in heritable retinoblastoma survivors: A report from the German reference center. *Pediatr. Blood Cancer* **2017**, *64*, 71–80. [\[CrossRef\]](#)
- Campeau, E.; Ruhl, V.E.; Rodier, F.; Smith, C.L.; Rahmberg, B.L.; Fuss, J.O.; Campisi, J.; Yaswen, P.; Cooper, P.K.; Kaufman, P.D. A versatile viral system for expression and depletion of proteins in mammalian cells. *PLoS ONE* **2009**, *4*, e6529. [\[CrossRef\]](#) [\[PubMed\]](#)
- Lawson, B.M.; Saktanasate, J.; Say, E.A.T.; Shields, C.L. Intravitreal chemotherapy provides control for massive vitreous seeding from retinoblastoma. *J. Pediatr. Ophthalmol. Strabismus* **2014**, *51*, e92–e94. [\[CrossRef\]](#) [\[PubMed\]](#)
- Manjandavida, F.P.; Shields, C.L. The role of intravitreal chemotherapy for retinoblastoma. *Indian J. Ophthalmol.* **2015**, *63*, 141–145. [\[CrossRef\]](#) [\[PubMed\]](#)
- Francis, J.H.; Abramson, D.H.; Ji, X.; Shields, C.L.; Teixeira, L.F.; Scheffler, A.C.; Cassoux, N.; Hadjistilianou, D.; Berry, J.L.; Frenkel, S.; et al. Risk of Extraocular Extension in Eyes With Retinoblastoma Receiving Intravitreal Chemotherapy. *JAMA Ophthalmol.* **2017**, *135*, 1426–1429. [\[CrossRef\]](#)
- Munier, F.L.; Gaillard, M.-C.; Balmer, A.; Beck-Popovic, M. Intravitreal chemotherapy for vitreous seeding in retinoblastoma: Recent advances and perspectives. *Saudi J. Ophthalmol.* **2013**, *27*, 147–150. [\[CrossRef\]](#)
- Shields, C.L.; Douglass, A.M.; Beggache, M.; Say, E.A.T.; Shields, J.A. Intravitreal Chemotherapy for Active Vitreous Seeding from Retinoblastoma: Outcomes after 192 Consecutive Injections. The 2015 Howard Naquin Lecture. *Retina* **2016**, *36*, 1184–1190. [\[CrossRef\]](#)
- Shields, C.L.; Lally, S.E.; Leahey, A.M.; Jabbour, P.M.; Caywood, E.H.; Schwendeman, R.; Shields, J.A. Targeted retinoblastoma management: When to use intravenous, intra-arterial, periocular, and intravitreal chemotherapy. *Curr. Opin. Ophthalmol.* **2014**, *25*, 374–385. [\[CrossRef\]](#)
- AlAli, A.; Kletke, S.; Gallie, B.; Lam, W.-C. Retinoblastoma for Pediatric Ophthalmologists. *Asia Pac. J. Ophthalmol.* **2018**, *7*, 160–168. [\[CrossRef\]](#)
- Soliman, S.E.; Racher, H.; Zhang, C.; MacDonald, H.; Gallie, B.L. Genetics and Molecular Diagnostics in Retinoblastoma—An Update. *Asia Pac. J. Ophthalmol.* **2017**, *6*, 197–207. [\[CrossRef\]](#)
- Soliman, S.E.; Wan, M.J.; Heon, E.; Hazrati, L.-N.; Gallie, B. Retinoblastoma versus advanced Coats’ disease: Is enucleation the answer? *Ophthalmic Genet.* **2017**, *38*, 291–293. [\[CrossRef\]](#) [\[PubMed\]](#)
- Ghiam, B.K.; Xu, L.; Berry, J.L. Aqueous Humor Markers in Retinoblastoma, a Review. *Transl. Vis. Sci. Technol.* **2019**, *8*, 13. [\[CrossRef\]](#) [\[PubMed\]](#)
- Busch, M.A.; Haase, A.; Miroshnikov, N.; Doege, A.; Biewald, E.; Bechrakis, N.E.; Beier, M.; Kanber, D.; Lohmann, D.; Metz, K.; et al. TFF1 in Aqueous Humor—A Potential New Biomarker for Retinoblastoma. *Cancers* **2022**, *14*, 677. [\[CrossRef\]](#) [\[PubMed\]](#)
- Martel, A.; Baillif, S.; Nahon-Esteve, S.; Gastaud, L.; Bertolotto, C.; Roméo, B.; Mograbi, B.; Lassalle, S.; Hofman, P. Liquid Biopsy for Solid Ophthalmic Malignancies: An Updated Review and Perspectives. *Cancers* **2020**, *12*, 3284. [\[CrossRef\]](#)

25. Fernández-Lázaro, D.; Hernández, J.L.G.; García, A.C.; Del Castillo, A.C.; Hueso, M.V.; Cruz-Hernández, J.J. Clinical Perspective and Translational Oncology of Liquid Biopsy. *Diagnostics* **2020**, *10*, 443. [\[CrossRef\]](#)
26. Berry, J.L.; Xu, L.; Murphree, A.L.; Krishnan, S.; Stachelek, K.; Zolfaghari, E.; McGovern, K.; Lee, T.C.; Carlsson, A.; Kuhn, P.; et al. Potential of Aqueous Humor as a Surrogate Tumor Biopsy for Retinoblastoma. *JAMA Ophthalmol.* **2017**, *135*, 1221–1230. [\[CrossRef\]](#)
27. Im, D.H.; Pike, S.; Reid, M.W.; Peng, C.-C.; Sirivolu, S.; Grossniklaus, H.E.; Hubbard, G.B.; Skalet, A.H.; Bellsmith, K.N.; Shields, C.L.; et al. A Multicenter Analysis of Nucleic Acid Quantification Using Aqueous Humor Liquid Biopsy in Retinoblastoma: Implications for Clinical Testing. *Ophthalmol. Sci.* **2023**, *3*, 100289. [\[CrossRef\]](#)
28. Ghose, N.; Kaliki, S. Liquid biopsy in Retinoblastoma: A review. *Semin. Ophthalmol.* **2022**, *37*, 813–819. [\[CrossRef\]](#)
29. Zhang, Z.; Wu, H.; Chong, W.; Shang, L.; Jing, C.; Li, L. Liquid biopsy in gastric cancer: Predictive and prognostic biomarkers. *Cell Death Dis.* **2022**, *13*, 903. [\[CrossRef\]](#)
30. Hou, Y.; Peng, Y.; Li, Z. Update on prognostic and predictive biomarkers of breast cancer. *Semin. Diagn. Pathol.* **2022**, *39*, 322–332. [\[CrossRef\]](#)
31. Freitas, A.J.A.D.; Causin, R.L.; Varuzza, M.B.; Calfa, S.; Hidalgo Filho, C.M.T.; Komoto, T.T.; Souza, C.D.P.; Marques, M.M.C. Liquid Biopsy as a Tool for the Diagnosis, Treatment, and Monitoring of Breast Cancer. *Int. J. Mol. Sci.* **2022**, *23*, 9952. [\[CrossRef\]](#) [\[PubMed\]](#)
32. Galardi, A.; Stathopoulos, C.; Colletti, M.; Lavarello, C.; Russo, I.; Cozza, R.; Romanzo, A.; Carcaboso, A.M.; Locatelli, F.; Petretto, A.; et al. Proteomics of Aqueous Humor as a Source of Disease Biomarkers in Retinoblastoma. *Int. J. Mol. Sci.* **2022**, *23*, 13458. [\[CrossRef\]](#) [\[PubMed\]](#)
33. Sun, J.; Xi, H.-Y.; Shao, Q.; Liu, Q.-H. Biomarkers in retinoblastoma. *Int. J. Ophthalmol.* **2020**, *13*, 325–341. [\[CrossRef\]](#)
34. Abramson, D.H.; Piro, P.A.; Ellsworth, R.M.; Kitchin, F.D.; McDonald, M. Lactate dehydrogenase levels and isozyme patterns. Measurements in the aqueous humor and serum of retinoblastoma patients. *Arch. Ophthalmol.* **1979**, *97*, 870–871. [\[CrossRef\]](#) [\[PubMed\]](#)
35. Piro, P.A., Jr.; Abramson, D.H.; Ellsworth, R.M.; Kitchin, D. Aqueous humor lactate dehydrogenase in retinoblastoma patients. Clinicopathologic correlations. *Arch. Ophthalmol.* **1978**, *96*, 1823–1825. [\[CrossRef\]](#) [\[PubMed\]](#)
36. Jiang, L.-B.; Liu, X.-Q.; Li, B.; He, X.-J.; Jin, Y.-L.; Li, L.-Q.; Gao, F.; Wang, N.-L. Heat shock proteins and survivin: Relationship and effects on proliferation index of retinoblastoma cells. *Histol. Histopathol.* **2008**, *23*, 827–831. [\[CrossRef\]](#) [\[PubMed\]](#)
37. Shehata, H.H.; Abou Ghalia, A.H.; Elsayed, E.K.; Ahmed Said, A.M.; Mahmoud, S.S. Clinical significance of high levels of survivin and transforming growth factor beta-1 proteins in aqueous humor and serum of retinoblastoma patients. *J. AAPOS* **2016**, *20*, 444.e1–444.e9. [\[CrossRef\]](#) [\[PubMed\]](#)
38. Busch, M.; Metz, K.; Beier, M.; Biewald, E.; Dünker, N. Trefoil factor family 1 expression correlates with clinical outcome in patients with retinoblastoma. *Retina* **2017**, *38*, 2422–2428. [\[CrossRef\]](#)
39. Hoffmann, W. Trefoil factors TFF (trefoil factor family) peptide-triggered signals promoting mucosal restitution. *Cell. Mol. Life Sci.* **2005**, *62*, 2932–2938. [\[CrossRef\]](#)
40. Hoffmann, W. Trefoil Factor Family (TFF) Peptides and Their Diverse Molecular Functions in Mucus Barrier Protection and More: Changing the Paradigm. *Int. J. Mol. Sci.* **2020**, *21*, 4535. [\[CrossRef\]](#)
41. Braga Emidio, N.; Brierley, S.M.; Schroeder, C.I.; Muttenthaler, M. Structure, Function, and Therapeutic Potential of the Trefoil Factor Family in the Gastrointestinal Tract. *ACS Pharmacol. Transl. Sci.* **2020**, *3*, 583–597. [\[CrossRef\]](#) [\[PubMed\]](#)
42. Heuer, J.; Heuer, F.; Stürmer, R.; Harder, S.; Schlüter, H.; Braga Emidio, N.; Muttenthaler, M.; Jechorek, D.; Meyer, F.; Hoffmann, W. The Tumor Suppressor TFF1 Occurs in Different Forms and Interacts with Multiple Partners in the Human Gastric Mucus Barrier: Indications for Diverse Protective Functions. *Int. J. Mol. Sci.* **2020**, *21*, 2508. [\[CrossRef\]](#) [\[PubMed\]](#)
43. Weise, A.; Dünker, N. High trefoil factor 1 (TFF1) expression in human retinoblastoma cells correlates with low growth kinetics, increased cyclin-dependent kinase (CDK) inhibitor levels and a selective down-regulation of CDK6. *Histochem. Cell Biol.* **2013**, *139*, 323–338. [\[CrossRef\]](#) [\[PubMed\]](#)
44. Philippeit, C.; Busch, M.; Dünker, N. Epigenetic control of trefoil factor family (TFF) peptide expression in human retinoblastoma cell lines. *Cell. Physiol. Biochem.* **2014**, *34*, 1001–1014. [\[CrossRef\]](#)
45. Busch, M.; Grosse-Kreul, J.; Wirtz, J.J.; Beier, M.; Stephan, H.; Royer-Pokora, B.; Metz, K.; Dünker, N. Reduction of the tumorigenic potential of human retinoblastoma cell lines by TFF1 overexpression involves p53/caspase signaling and miR-18a regulation. *Int. J. Cancer* **2017**, *141*, 549–560. [\[CrossRef\]](#)
46. Katsha, A.; Soutto, M.; Sehdev, V.; Peng, D.; Washington, M.K.; Piazzuelo, M.B.; Tantawy, M.N.; Manning, H.C.; Lu, P.; Shyr, Y.; et al. Aurora kinase A promotes inflammation and tumorigenesis in mice and human gastric neoplasia. *Gastroenterology* **2013**, *145*, 1312–1322.e8. [\[CrossRef\]](#) [\[PubMed\]](#)
47. Soutto, M.; Chen, Z.; Saleh, M.A.; Katsha, A.; Zhu, S.; Zaika, A.; Belkhiri, A.; El-Rifai, W. TFF1 activates p53 through down-regulation of miR-504 in gastric cancer. *Oncotarget* **2014**, *5*, 5663–5673. [\[CrossRef\]](#)
48. Busch, M.; Philippeit, C.; Weise, A.; Dünker, N. Re-characterization of established human retinoblastoma cell lines. *Histochem. Cell Biol.* **2015**, *143*, 325–338. [\[CrossRef\]](#)
49. Eide, N.; Walaas, L. Fine-needle aspiration biopsy and other biopsies in suspected intraocular malignant disease: A review. *Acta Ophthalmol.* **2009**, *87*, 588–601. [\[CrossRef\]](#)
50. Karcioglu, Z.A. Fine needle aspiration biopsy (FNAB) for retinoblastoma. *Retina* **2002**, *22*, 707–710. [\[CrossRef\]](#)

51. Ali, M.J.; Honavar, S.G.; Vemuganti, G.K.; Singh, A.D. Fine needle aspiration biopsy of retinal tumors. *Monogr. Clin. Cytol.* **2012**, *21*, 72–81. [[CrossRef](#)] [[PubMed](#)]
52. Raval, V.; Racher, H.; Wrenn, J.; Singh, A.D. Aqueous humor as a surrogate biomarker for retinoblastoma tumor tissue. *J. AAPOS* **2022**, *26*, 137.e1–137.e5. [[CrossRef](#)] [[PubMed](#)]
53. Smith, S.J.; Smith, B.D. Evaluating the risk of extraocular tumour spread following intravitreal injection therapy for retinoblastoma: A systematic review. *Br. J. Ophthalmol.* **2013**, *97*, 1231–1236. [[CrossRef](#)] [[PubMed](#)]
54. Ghassemi, F.; Shields, C.L.; Ghadimi, H.; Khodabandeh, A.; Roohipoor, R. Combined intravitreal melphalan and topotecan for refractory or recurrent vitreous seeding from retinoblastoma. *JAMA Ophthalmol.* **2014**, *132*, 936–941. [[CrossRef](#)] [[PubMed](#)]
55. Francis, J.H.; Schaiquevich, P.; Buitrago, E.; Del Sole, M.J.; Zapata, G.; Croxatto, J.O.; Marr, B.P.; Brodie, S.E.; Berra, A.; Chantada, G.L.; et al. Local and systemic toxicity of intravitreal melphalan for vitreous seeding in retinoblastoma: A preclinical and clinical study. *Ophthalmology* **2014**, *121*, 1810–1817. [[CrossRef](#)] [[PubMed](#)]
56. Smith, S.J.; Smith, B.D.; Mohney, B.G. Ocular side effects following intravitreal injection therapy for retinoblastoma: A systematic review. *Br. J. Ophthalmol.* **2014**, *98*, 292–297. [[CrossRef](#)] [[PubMed](#)]
57. Uner, O.E.; Ulrich, B.C.; Hubbard, G.B. Potential of Aqueous Humor as a Surrogate Tumor Biopsy for Retinoblastoma. *JAMA Ophthalmol.* **2018**, *136*, 597–598. [[CrossRef](#)]
58. Liu, W.; Luo, Y.; Dai, J.; Yang, L.; Huang, L.; Wang, R.; Chen, W.; Huang, Y.; Sun, S.; Cao, J.; et al. Monitoring Retinoblastoma by Machine Learning of Aqueous Humor Metabolic Fingerprinting. *Small Methods* **2022**, *6*, e2101220. [[CrossRef](#)]
59. Berry, J.L.; Xu, L.; Polski, A.; Jubran, R.; Kuhn, P.; Kim, J.W.; Hicks, J. Aqueous Humor Is Superior to Blood as a Liquid Biopsy for Retinoblastoma. *Ophthalmology* **2020**, *127*, 552–554. [[CrossRef](#)]
60. Yi, J.; Ren, L.; Li, D.; Wu, J.; Li, W.; Du, G.; Wang, J. Trefoil factor 1 (TFF1) is a potential prognostic biomarker with functional significance in breast cancers. *Biomed. Pharmacother.* **2020**, *124*, 109827. [[CrossRef](#)]
61. Schulten, H.-J.; Bangash, M.; Karim, S.; Dallol, A.; Hussein, D.; Merdad, A.; Al-Thoubaity, F.K.; Al-Maghrabi, J.; Jamal, A.; Al-Ghamdi, F.; et al. Comprehensive molecular biomarker identification in breast cancer brain metastases. *J. Transl. Med.* **2017**, *15*, 269. [[CrossRef](#)] [[PubMed](#)]
62. Gonzaga, I.M.; Soares Lima, S.C.; Nicolau, M.C.; Nicolau-Neto, P.; da Costa, N.M.; de Almeida Simão, T.; Hernandez-Vargas, H.; Herceg, Z.; Ribeiro Pinto, L.F. TFF1 hypermethylation and decreased expression in esophageal squamous cell carcinoma and histologically normal tumor surrounding esophageal cells. *Clin. Epigenet.* **2017**, *9*, 130. [[CrossRef](#)] [[PubMed](#)]
63. Shimura, T.; Dayde, D.; Wang, H.; Okuda, Y.; Iwasaki, H.; Ebi, M.; Kitagawa, M.; Yamada, T.; Yamada, T.; Hanash, S.M.; et al. Novel urinary protein biomarker panel for early diagnosis of gastric cancer. *Br. J. Cancer* **2020**, *123*, 1656–1664. [[CrossRef](#)]
64. Elnagdy, M.H.; Farouk, O.; Seleem, A.K.; Nada, H.A. TFF1 and TFF3 mRNAs Are Higher in Blood from Breast Cancer Patients with Metastatic Disease than Those without. *J. Oncol.* **2018**, *2018*, 4793498. [[CrossRef](#)] [[PubMed](#)]

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.